Infectious Diseases
2 ANCC Contact Hours 2 AMA PRA Category 1 Credit(s)
Launch Date:
May 29, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, Nurse Practitioners, Physician Assistants, Registered Nurses, and all interested health care providers involved in the treatment of patients with HIV.

Relevant Terms:

The New Guidelines And The Emergence Of New Agents, Best Practices In The Treatment Of HIV-infected Persons, Conifections, Comorbidities, Initiation Of Treatment, Resistance And Retention.

Donna E. Sweet, MD

Donna E. Sweet, MD
Professor of Medicine
Department of Internal Medicine
University of Kansas School of Medicine
Director, HIV Programs
The Medical Practice Association of the
University of Kansas School of Medicine
Wichita, KS

Dr. Sweet is Professor of Internal Medicine at the University of Kansas School of Medicine-Wichita. She is Director of Internal Medicine Education at Via Christi Regional Medical Center - St. Francis, as well as the director and principal investigator of the Kansas AIDS Education and Training Center. In addition, she is a past president and current member of the Advisory Board for the Sedgwick County Board of Health. Dr. Sweet is the immediate past Chair of the Board of Regents for The American College of Physicians (ACP), and continues in the organization through her participation on national committees and by working with the College's Eurasian Medical Education program. She has traveled to various parts of the Russian Far East over the past two years providing HIV education to physicians in order to further prevention and treatment efforts there.
Dr. Sweet has been recognized both locally and nationally for treatment and research on HIV/AIDS. She currently serves on the Center for Disease Control/ Health Resource Services Administration's Advisory Council on HIV/AIDS and is a member of the national board for the American Academy of HIV Medicine. In addition, she has served on the planning committee of the National AIDS Update Conference for AmFAR and recently co-chaired The National Ryan White Clinical Update Conference in Washington, D.C.
In 1995, Dr. Sweet was one of only 130 researchers and clinicians nation-wide invited to take part in the first White House Conference on HIV and AIDS. She also received the "Award of Courage" from the American Foundation for AIDS Research on World AIDS Day 1992 and was recognized on World AIDS Day 1993 by the Health Care Financing Administration with an "Administrators Citation" for her willingness to treat HIV infected individuals without regard to their ability to pay. She continues to lecture both locally and nationally to educate other health care providers regarding HIV.
Her role with the Mountain Plains AIDS Education and Training Center takes her across the US delivering HIV prevention and treatment messages. As Clinical Director of the only Ryan White Title III Early Intervention and Treatment Grant in Kansas, she cares for over 850 Kansans with HIV/AIDS.

Sally L. Hodder, MD

Sally L. Hodder, MD
Professor of Medicine
New Jersey Medical School
University of Medicine and Dentistry of New Jersey
Newark, NJ

Dr. Hodder received her BA from the Mount Holyoke College and her MD from Case Western Reserve University. She was a fellow in the Infectious Disease Division at CASE Western/University Hospitals in Cleveland, where she also worked as an attending physician, consultant and Associate Professor until 1999. She then joined Bristol-Myers Squibb Company as a sub team leader in the medical affairs organization during the acquisition of DuPont Pharma. She was later appointed Senior Director of U.S. Virology Scientific Operations and a few months later was promoted to be the Vice-President of the U.S. Virology Medical Affairs. In February 2005 she joined the Infectious Disease Division at New Jersey Medical School. Dr. Hodder has received numerous awards including the President's award from Bristol-Myers Squibb Co, she has been a member in different committees such as the National Board of Medical Examiners and the National coalition to eliminate tuberculosis. She has published in many scientific and medical journals. Dr. Hodder is now the Executive Vice-chair of the Department and also the Director of HIV services at the University Hospital.

Douglas Ward, MD              

Douglas Ward, MD              
Clinical Associate Professor              
George Washington School of Medicine        
Dupont Circle Physicians Group       
Washington, DC    

1. Identify for testing all patients in their practices with an unknown HIV status and those at continued high risk for infection
2. Utilize data and concepts from clinical studies and evidence-based guidelines to initiate treatment in all HIV-infected patients
3. Describe how to incorporate new research data and evidence-based guideline recommendations into clinical practice to minimize adverse events and achieve and maintain maximal viral suppression with ART in all HIV-infected patients
4. Implement treatment strategies based on clinical data and expert recommendations to treat HIV-infected patients with comorbidities and coinfections

Thursday, May 29, 2014
The Oceanaire Seafood Room
Washington, DC

Target Audience
The educational design of this activity addresses the needs of physicians, physician assistants, nurse practitioners, registered nurses, and all interested health care providers involved in the treatment of patients with HIV.

Program Overview
Advances in research and an expansion of antiretroviral therapy (ART) options now enable HIV-infected persons to live near-normal lifespans. However, deficits in quality HIV care from treatment initiation throughout long-term retention persist across the spectrum of care. HIV-infected patients can present significant treatment challenges to health care providers with respect to the initiation of treatment, retention, resistance, coinfections, and comorbidities. The recent approval and anticipated arrival of new agents and new combinations, for both treatment-naive and treatment-experienced patients, as well as newly released HIV professional treatment guidelines, highlight the need for continuing medical education (CME). This CME activity presents best practices in the treatment of HIV-infected persons based on the new guidelines and the emergence of new agents to assist you in making informed care and treatment decisions. In addition, it will provide you with the opportunity to immediately put this new knowledge into virtual clinical practice.

7:00 PM – 7:05 PM              Welcome and Introduction
7:05 PM – 7:35 PM              Overview of Best Practices in HIV Management and Care
7:35 PM – 8:35 PM              Interactive Case Study
8:35 PM – 8:55 PM              Panel Discussion/Post Program Assessment 
8:55 PM – 9:00 PM              Closing Remarks

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and HealthmattersCME. Global is accredited by the ACCME to provide continuing medical education for physicians..
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
This educational activity for 2 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
For information about the accreditation of this program, please contact Global at 303-395-1782 or
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Reported Financial Relationship
Sally L. Hodder, MD
Consultant/Independent Contractor: Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen; Merck
Grant/Research Support: Gilead Sciences, Inc.; ViiV Healthcare
Stock Shareholder: Merck
Donna E. Sweet, MD
Consultant/Independent Contractor: Pfizer
Speaker's Bureau: Bristol-Myers Squibb; Gilead Sciences, Inc. 
Douglas Ward, MD
Grant/Research Support: Gilead Sciences, Inc.; EMD Serono; ViiV Healthcare
Honoraria: Gilead Sciences, Inc.; ViiV Healthcare
Stock Shareholder: Gilead Sciences, Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
Andrea Funk Nothing to disclose
Amanda Glazar, PhD Nothing to disclose
Stacey Hansen Nothing to disclose
Ashley Marostica, RN, MSN Nothing to disclose
James Murphy Nothing to disclose

This activity is jointly sponsored by Global Education Group and HealthmattersCME.
This activity is co-provided by Global Education Group and HealthmattersCME.

This activity is supported by an independent educational grant from Gilead Sciences
Medical Affairs.

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above